Target Information

Target General Infomation
Target ID
T46128
Former ID
TTDI02331
Target Name
Melanocytes lineage-specific antigen GP100
Gene Name
PMEL
Synonyms
ME20M; ME20S; Mbeta; Melanocyte protein PMEL; Melanocyte protein Pmel 17; Melanomaassociated ME20 antigen; P1; P100; Premelanosome protein; Silver locus protein homolog; PMEL
Target Type
Clinical Trial
Disease Melanoma [ICD9: 172; ICD10: C43]
Function
Plays a central role in the biogenesis of melanosomes. Involved in the maturation of melanosomes from stage I to II. The transition from stage I melanosomes to stage II melanosomes involves an elongation of the vesicle, and the appearance within of distinct fibrillar structures. Release of the soluble form, ME20-S, could protect tumor cells from antibody mediated immunity.
BioChemical Class
PMEL/NMB family
UniProt ID
P40967
Sequence
MDLVLKRCLLHLAVIGALLAVGATKVPRNQDWLGVSRQLRTKAWNRQLYPEWTEAQRLDC
WRGGQVSLKVSNDGPTLIGANASFSIALNFPGSQKVLPDGQVIWVNNTIINGSQVWGGQP
VYPQETDDACIFPDGGPCPSGSWSQKRSFVYVWKTWGQYWQVLGGPVSGLSIGTGRAMLG
THTMEVTVYHRRGSRSYVPLAHSSSAFTITDQVPFSVSVSQLRALDGGNKHFLRNQPLTF
ALQLHDPSGYLAEADLSYTWDFGDSSGTLISRALVVTHTYLEPGPVTAQVVLQAAIPLTS
CGSSPVPGTTDGHRPTAEAPNTTAGQVPTTEVVGTTPGQAPTAEPSGTTSVQVPTTEVIS
TAPVQMPTAESTGMTPEKVPVSEVMGTTLAEMSTPEATGMTPAEVSIVVLSGTTAAQVTT
TEWVETTARELPIPEPEGPDASSIMSTESITGSLGPLLDGTATLRLVKRQVPLDCVLYRY
GSFSVTLDIVQGIESAEILQAVPSGEGDAFELTVSCQGGLPKEACMEISSPGCQPPAQRL
CQPVLPSPACQLVLHQILKGGSGTYCLNVSLADTNSLAVVSTQLIMPGQEAGLGQVPLIV
GILLVLMAVVLASLIYRRRLMKQDFSVPQLPHSSSHWLRLPRIFCSCPIGENSPLLSGQQ
V
Drugs and Mode of Action
Drug(s) Melanoma vaccine Drug Info Phase 3 Melanoma [521514]
Multi-epitope peptide melanoma vaccine Drug Info Phase 3 Melanoma [521514]
Gp100:209-217(210M) peptide vaccine Drug Info Phase 2 Melanoma [521456]
IMCgp100 Drug Info Phase 2 Melanoma [889433]
Multi-epitope tyrosinase/gp100 vaccine Drug Info Phase 2 Melanoma [521451]
AE-08 Drug Info Phase 1 Melanoma [549441]
Melanoma vaccine Drug Info Discontinued in Phase 2 Melanoma [547218]
Modulator IMCgp100 Drug Info
Target Expression Profile (TEP) and Drug Resistance Mutation (DRM)
TEP EXP Info
References
Ref 521451ClinicalTrials.gov (NCT00003362) Vaccine Therapy Plus Immune Adjuvants in Treating Patients With Advanced Melanoma. U.S. National Institutes of Health.
Ref 521456ClinicalTrials.gov (NCT00003895) Vaccine Therapy in Treating HLA-A2 Positive Patients With Melanoma. U.S. National Institutes of Health.
Ref 521514ClinicalTrials.gov (NCT00036816) Vaccine Therapy in Treating Patients With Melanoma of the Eye. U.S. National Institutes of Health.
Ref 547218Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800014153)
Ref 549441Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800037366)
Ref 889433ClinicalTrials.gov (NCT03070392) Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma
Ref 521451ClinicalTrials.gov (NCT00003362) Vaccine Therapy Plus Immune Adjuvants in Treating Patients With Advanced Melanoma. U.S. National Institutes of Health.
Ref 530817Synthesis of labeled BCX-4208, a potent inhibitor of purine nucleoside phosphorylase. Drug Test Anal. 2009 Mar;1(3):125-7.
Ref 531162Preclinical qualification of a new multi-antigen candidate vaccine for metastatic melanoma. J Immunother. 2010 Oct;33(8):743-58.
Ref 544270Safety and immunogenicity of vaccination with MART-1 (26-35, 27L), gp100 (209-217, 210M), and tyrosinase (368-376, 370D) in-adjuvant with PF-3512676 and GM-CSF in metastatic melanoma. Correction in: volume 35 on page 650.
Ref 550405National Cancer Institute Drug Dictionary (drug id 476335).
Ref 550463National Cancer Institute Drug Dictionary (drug id 685201).

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.